Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
Indaptus Therapeutics宣佈完成首例接受多劑量Decoy20的患者，這是該公司針對晚期實體瘤的基礎廣泛的 “脈衝式” 免疫腫瘤學療法